Method of treating solid cancers with bispecific interleukin-anti-TCRß molecules
US11965025B2 · kind B2 · utility
5Cited by
104References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 18, 2022 |
| Grant date | Apr 23, 2024 |
| Priority date | — |
| Expiry date | Aug 18, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.